1-6 of 6
Glenn Kroog
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

Free
Meletios Dimopoulos, Sosana Delimpasi, Salomon Manier, Jean-Marie Michot, Enrique Ocio, Samuel Rubinstein, Joselle Cook, Maria Del Carmen Martinez Chamorro, Aurora Breazna, Amishi Dhadwal, Yogita Ghodke, Sheila Masinde, Glenn Kroog, Shawn Sarkaria, Albert Oriol
Journal: Blood
Blood (2025) 146 (Supplement 1): 2254.
https://doi.org/10.1182/blood-2025-2254
Published: 2025
Journal Articles

Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US

Free
Sikander Ailawadhi, Thomas Delea, Olivier Humblet, Timothy Inocencio, Mengying Li, Alexandra Bryan, Aaron Moynahan, Glenn Kroog, Christian Hampp, Michelle Little, Qiufei Ma
Journal: Blood
Blood (2025) 146 (Supplement 1): 3975.
https://doi.org/10.1182/blood-2025-3975
Published: 2025
Journal Articles

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Free
Robert Orlowski, Mansi Shah, Rajshekhar Chakraborty, Pascual Fernandez-Abellán, Xavier Leleu, Albert Oriol, Henning Schade, Don Stevens, Laurent Garderet, Sarah Larson, Lisa Lee, Jean-Marie Michot, Gareth Morgan, Michael Schuster, Aurora Breazna, Oluwaseun Aina, Amishi Dhadwal, Jennifer Sims, Colby S. Shemesh, Anasuya Hazra, Daniel Lee, Glenn Kroog, Karen Rodriguez Lorenc, Steven E. Quatela, Christopher Ferreri
Journal: Blood
Blood (2025) 146 (Supplement 1): 697.
https://doi.org/10.1182/blood-2025-697
Published: 2025
Journal Articles

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Free
Paul G. Richardson, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD, PhD, Marc S Raab, Thierry Facon, MD, Ravi Vij, MBBS, Darrell J. White, MD, Donna Reece, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Wei Deng, Glenn Kroog, MD, Anil K Singhal, MD, Sagar Lonial, MD
Journal: Blood
Blood (2012) 120 (21): 202.
https://doi.org/10.1182/blood.V120.21.202.202
Published: 2012
Journal Articles

Investigation of the Association Between Treatment Effects On Progression Free Survival and Overall Survival in Multiple Myeloma Using Data From Published Literature

Free
Bin Zhang, Shannon Cartier, Virginia Rosen, April Teitelbaum, Ying Zhang, Blake J Bartlett, PhD, Glenn Kroog, MD, Pralay Mukhopadhyay, Samuel Wagner, PhD, RPh
Journal: Blood
Blood (2012) 120 (21): 4241.
https://doi.org/10.1182/blood.V120.21.4241.4241
Published: 2012
Journal Articles

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Free
Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MD, Philippe Moreau, MD, Donna E. Reece, MD, FRCPC, Darrell J. White, MD, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Jean-Francois Rossi, MD, PhD, Claire Tsao, Teresa Parli, Glenn Kroog, MD, Anil K Singhal, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 303.
https://doi.org/10.1182/blood.V118.21.303.303
Published: 2011